Once-Daily Asenapine for Schizophrenia

Completed · Phase 4

Conditions studied: Schizophrenia

In brief

The investigators propose to explore: 1. the acceptance by patients of once versus twice daily dosing with asenapine, 2. the acceptance by staff of once versus twice daily dosing with asenapine, and 3. the changes in psychopathology associated with these two dosing strategies, in 30 patients with schizophrenia or schizoaffective disorder. The investigators hypothesize that patient and staff acceptance will be better with once daily dosing and that improvements in psychopathology will be similar across once daily and twice daily dosing

Key facts

Study ID

NCT01549041

Run by

Duke University

People needed

30

Starts

2012-04-01

Expected to finish

2013-11-01

Last updated by the study team

2014-05-26

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female individuals,
• 18-65 years of age,
• who meet DSM-IV diagnostic criteria for schizophrenia or schizoaffective disorder,
• who are newly admitted to Central Regional Hospital for treatment of an acute psychotic exacerbation,
• who provide signed informed consent to participate, will be included.

You may not qualify if…

• Females who are lactating or pregnant,
• individuals with a prior history of poor therapeutic response or sensitivity to asenapine, will be excluded

Where it is running

• Central Regional Hospital — Butner, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.